Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.01 USD | +0.61% | -2.29% | -10.06% |
05-03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
05-02 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
End-of-day quotes
Sector Bio Therapeutic Drugs
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
3.57B | - | |||||
106B | ||||||
104B | ||||||
23.25B | - | |||||
22.5B | - | |||||
18.7B |